Ipilimumab Combination Dosing: Less is More.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34341015.
- Also identified by DOI 10.1158/1078-0432.CCR-21-2406 and PMC identifier 8807780.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ipilimumab with and without anti-Programmed Death 1 (PD-1) improved overall survival (OS) in melanoma. Despite this, the optimal dose and therapeutic mechanism of ipilimumab in patients remains unclear. KEYNOTE-029 and other studies suggest that low-dose ipilimumab with anti-PD1 maintains efficacy while decreasing toxicity, emphasizing T-cell trafficking and reinvigoration as likely mechanisms. See related article by Long et al., p. 5280.
Medical subject headings
- Melanoma